Bayer: to start new Phase III trials on eye drug Eylea
(CercleFinance.com) - Bayer and Regeneron said on Monday they will start two late-stage trials on new formulation of eye drug Eylea in patients with visual impairment due to diabetic macular edema and wet age-related macular degeneration.
The randomized trials - which are planned to start in 2020 - will assess the efficacy and safety of 8mg formulation in treatment regimes of three months and greater, the drugmakers said.
Regeneron holds exclusive rights to Eylea in the United States, but Bayer has licensed the exclusive marketing rights outside the United States, where the companies equally share the profits.
Eylea is currently approved in more than 100 countries for five indications.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The randomized trials - which are planned to start in 2020 - will assess the efficacy and safety of 8mg formulation in treatment regimes of three months and greater, the drugmakers said.
Regeneron holds exclusive rights to Eylea in the United States, but Bayer has licensed the exclusive marketing rights outside the United States, where the companies equally share the profits.
Eylea is currently approved in more than 100 countries for five indications.
Copyright (c) 2020 CercleFinance.com. All rights reserved.